View Document Preview and Link Document Date: 2013-02-21 00:17:52 Open Document File Size: 346,10 KB Share Result on Facebook
City Athens / San Francisco / San Diego / New York / / Company CIRM / ViaCyte Inc. / JDRF / / Currency USD / / Event FDA Phase / / Facility California Institute / / IndustryTerm care of people with this disease / durable and retrievable encapsulation device / encapsulation device / combination product / treatment of diabetes / cell encapsulation product / implanted using a durable and retrievable encapsulation device / / MedicalCondition insulin-dependent diabetes / disease / diabetes-related complications / diabetes / hypoglycemia / / MedicalTreatment cell therapy / / MusicGroup Ph.D. / / Organization JDRF JDRF / U.S. Food and Drug Administration / JDRF’s mission / California Institute for Regenerative Medicine / / Person Paul Laikind / Julia Greenstein / Ellen Feigal / / Position senior vice president for research and development / vice president of cure therapies / chief executive officer and president / / Product VC-01 / / ProvinceOrState California / New York / Georgia / / Technology cell therapy / stem cells / Regenerative Medicine / on developing a novel cell therapy / / URL http / SocialTag 
JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte -- Treatment being developed would use encapsulation to protect new insulin-producing cells derived from a stem cell precursor -New York